Nature Communications (Jan 2020)
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
- Fara Brasó-Maristany,
- Gaia Griguolo,
- Tomás Pascual,
- Laia Paré,
- Paolo Nuciforo,
- Antonio Llombart-Cussac,
- Begoña Bermejo,
- Mafalda Oliveira,
- Serafín Morales,
- Noelia Martínez,
- Maria Vidal,
- Barbara Adamo,
- Olga Martínez,
- Sonia Pernas,
- Rafael López,
- Montserrat Muñoz,
- Núria Chic,
- Patricia Galván,
- Isabel Garau,
- Luis Manso,
- Jesús Alarcón,
- Eduardo Martínez,
- Sara Gregorio,
- Roger R. Gomis,
- Patricia Villagrasa,
- Javier Cortés,
- Eva Ciruelos,
- Aleix Prat
Affiliations
- Fara Brasó-Maristany
- Department of Medical Oncology, Hospital Clínic de Barcelona
- Gaia Griguolo
- Department of Medical Oncology, Hospital Clínic de Barcelona
- Tomás Pascual
- Department of Medical Oncology, Hospital Clínic de Barcelona
- Laia Paré
- SOLTI Breast Cancer Research Group
- Paolo Nuciforo
- Vall d’Hebrón University Hospital
- Antonio Llombart-Cussac
- Hospital Universitario Arnau de Vilanova
- Begoña Bermejo
- Hospital Clínico Universitario de Valencia
- Mafalda Oliveira
- Vall d’Hebrón University Hospital
- Serafín Morales
- Hospital Universitario Arnau de Vilanova
- Noelia Martínez
- Hospital Universitario Ramón y Cajal
- Maria Vidal
- Department of Medical Oncology, Hospital Clínic de Barcelona
- Barbara Adamo
- Department of Medical Oncology, Hospital Clínic de Barcelona
- Olga Martínez
- Department of Medical Oncology, Hospital Clínic de Barcelona
- Sonia Pernas
- SOLTI Breast Cancer Research Group
- Rafael López
- Hospital Clínico Universitario de Santiago, Rúa da Choupana, s/n
- Montserrat Muñoz
- Department of Medical Oncology, Hospital Clínic de Barcelona
- Núria Chic
- Department of Medical Oncology, Hospital Clínic de Barcelona
- Patricia Galván
- Department of Medical Oncology, Hospital Clínic de Barcelona
- Isabel Garau
- Hospital Son Llàtzer, Ctra. de Manacor
- Luis Manso
- Hospital Universitario 12 de Octubre, Av. de Córdoba, s/n
- Jesús Alarcón
- Hospital Universitario Son Espases
- Eduardo Martínez
- Consorcio Hospitalario Provincial de Castellón
- Sara Gregorio
- Institute for Research in Biomedicine
- Roger R. Gomis
- Institute for Research in Biomedicine
- Patricia Villagrasa
- SOLTI Breast Cancer Research Group
- Javier Cortés
- Vall d´Hebron Institute of Oncology (VHIO)
- Eva Ciruelos
- SOLTI Breast Cancer Research Group
- Aleix Prat
- Department of Medical Oncology, Hospital Clínic de Barcelona
- DOI
- https://doi.org/10.1038/s41467-019-14111-3
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 11
Abstract
HER2-enriched breast cancers within the HER2-positive subtype are addicted to the HER2 pathway. Here, the authors analyse gene expression before, during, and after treatment with anti-HER2-based therapies in the phase II PAMELA clinical trial, finding phenotypic changes induced by treatment.
